Brief: Garetosmab Biologics License Application Accepted For FDA Priority Review
19/02/2026 12:09
Feb 19 (Reuters) - Regeneron Pharmaceuticals Inc REGN.O: GARETOSMAB BIOLOGICS LICENSE APPLICATION ACCEPTED FOR FDA PRIORITY REVIEW FOR THE TREATMENT OF FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP) REGENERON PHARMACEUTICALS INC - FDA DECISION EXPECTED BY AUGUST 2026 Source text: ID:nGNX3Qxbxp Further company coverage: REGN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Regeneron Pharmaceuticals
See all newsLilly, Regeneron selected for US program to review new manufacturing plants faster (updated)
FDA selects Lilly, Regeneron for program to speed up review of new manufacturing facilities, CNBC reports
Brief: Eli Lilly, Regeneron Among First Companies Selected For FDA Initiative To Speed Review Of New Manufacturing Facilities - CNBC
Brief: Cemdisiran Regulatory Submissions Accepted For Review By FDA And EMA For The Treatment Of Generalized Myasthenia Gravis (Gmg)
AbbVie sharpens immunology focus with $10.9 billion Apogee deal (updated)